Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
This is a multicenter, Phase 1b study with dose escalation and expansion cohorts designed to assess the safety, tolerability, PK, and preliminary efficacy of PU-H71 in subjects with PMF, Post-PV MF, Post-ET MF, taking stable doses of ruxolitinib.
Primary Myelofibrosis (PMF)|Post-Polycythemia Vera Myelofibrosis (Post-PV MF)|Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
DRUG: PU-H71
Assess Safety, Tolerability and Pharmacokinetics of PU-H71, Determine the human exposure PK including Cmax, 24 weeks|Assess Safety, Tolerability and Pharmacokinetics of PU-H71, Determine the human exposure PK including Tmax, 24 weeks|Assess Safety, Tolerability and Pharmacokinetics of PU-H71, Determine the human exposure PK including AUC0-t, 24 weeks|Assess Safety, Tolerability and Pharmacokinetics of PU-H71, Determine the human exposure PK including AUC0-inf, 24 weeks|Assess Safety, Tolerability and Pharmacokinetics of PU-H71, Determine the human exposure PK including CL, 24 weeks|Assess Safety, Tolerability and Pharmacokinetics of PU-H71, Determine the human exposure PK including t1/2, 24 weeks|Assess Safety and Tolerability of PU-H71, Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in physical examinations, 24 weeks|Assess Safety and Tolerability of PU-H71, Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in electrocardiograms (ECGs), 24 weeks|Assess Safety and Tolerability of PU-H71, Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in vital signs, 24 weeks|Assess Safety and Tolerability of PU-H71, Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in clinical laboratory evaluations, 24 weeks|Assess treatment response of PU H71, Treatment response in myelofibrosis (MF) is to be evaluated using the revised International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT), 24 weeks|Assess treatment response of PU H71, Treatment response in myelofibrosis (MF) is to be evaluated using the revised European LeukemiaNet (ELN) response criteria., 24 weeks
The study will employ a standard 3+3 dose escalation design to determine maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), with additional subjects treated in a dose expansion cohort. The time period for collecting dose limiting toxicities (DLTs) is 1 cycle (21 days).